Total Payments
$1,311
2024 Payments
$142.82
Companies
24
Transactions
53
Medicare Patients
1,689
Medicare Billing
$269,711
Payment Breakdown by Category
Food & Beverage$972.30 (74.2%)
Other$299.10 (22.8%)
Education$39.32 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $972.30 | 48 | 74.2% |
| Long term medical supply or device loan | $299.10 | 3 | 22.8% |
| Education | $39.32 | 2 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $376.10 | 7 | $0 (2023) |
| Genentech, Inc. | $120.38 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $107.46 | 6 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $106.16 | 6 | $0 (2020) |
| Daiichi Sankyo Inc. | $91.47 | 5 | $0 (2022) |
| Genentech USA, Inc. | $72.01 | 4 | $0 (2020) |
| Amgen Inc. | $62.64 | 3 | $0 (2022) |
| Karyopharm Therapeutics Inc. | $38.67 | 1 | $0 (2020) |
| Puma Biotechnology, Inc. | $32.04 | 2 | $0 (2020) |
| Seagen Inc. | $29.57 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $142.82 | 3 | Genentech, Inc. ($120.38) |
| 2023 | $344.50 | 5 | Novartis Pharmaceuticals Corporation ($323.81) |
| 2022 | $77.40 | 4 | E.R. Squibb & Sons, L.L.C. ($24.50) |
| 2021 | $32.42 | 2 | Global Blood Therapeutics, Inc. ($17.88) |
| 2020 | $430.38 | 22 | AstraZeneca Pharmaceuticals LP ($56.38) |
| 2019 | $185.87 | 11 | Genentech USA, Inc. ($37.92) |
| 2018 | $97.33 | 6 | E.R. Squibb & Sons, L.L.C. ($30.21) |
All Payment Transactions
53 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Genentech, Inc. | Itovebi (Biological) | Food and Beverage | In-kind items and services | $74.93 | General |
| Category: BioOncology | ||||||
| 11/15/2024 | Genentech, Inc. | Itovebi (Biological) | Food and Beverage | In-kind items and services | $45.45 | General |
| Category: BioOncology | ||||||
| 11/01/2024 | Janssen Scientific Affairs, LLC | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: Oncology | ||||||
| 09/12/2023 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: HEMATOLOGY | ||||||
| 05/31/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| 05/24/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Oncology | ||||||
| 02/15/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| 01/14/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| 11/10/2022 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/10/2022 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Education | In-kind items and services | $24.50 | General |
| Category: Hematology | ||||||
| 04/27/2022 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Oncology | ||||||
| 02/17/2022 | Astellas Pharma US Inc | Padcev (Drug) | Education | In-kind items and services | $14.82 | General |
| Category: Oncology | ||||||
| 11/19/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA, PIQRAY | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: ONCOLOGY | ||||||
| 07/14/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 08/04/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.49 | General |
| Category: Oncology | ||||||
| 07/08/2020 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $17.22 | General |
| Category: Oncology | ||||||
| 06/30/2020 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $21.00 | General |
| 06/24/2020 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.86 | General |
| Category: Hematology | ||||||
| 06/10/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.40 | General |
| Category: Oncology | ||||||
| 06/09/2020 | Puma Biotechnology, Inc. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2020 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $32.41 | General |
| Category: Bone Health | ||||||
| 06/01/2020 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.40 | General |
| Category: Oncology | ||||||
| 05/27/2020 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $25.15 | General |
| Category: Oncology | ||||||
| 05/19/2020 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: Anemia | ||||||
| 03/04/2020 | Genentech USA, Inc. | Avastin (Biological), Rituxan, Herceptin | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 352 | 625 | $191,300 | $57,755 |
| 2022 | 6 | 444 | 843 | $253,290 | $81,257 |
| 2021 | 6 | 401 | 732 | $173,972 | $69,659 |
| 2020 | 8 | 492 | 796 | $147,811 | $61,041 |
Total Patients
1,689
Total Services
2,996
Medicare Billing
$269,711
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 203 | 396 | $118,552 | $36,470 | 30.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 57 | 98 | $39,440 | $12,690 | 32.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 41 | 57 | $11,585 | $3,448 | 29.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $12,652 | $3,232 | 25.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $5,099 | $1,219 | 23.9% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 18 | 41 | $3,972 | $695.96 | 17.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 236 | 537 | $159,489 | $51,026 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 77 | 126 | $50,400 | $17,269 | 34.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 39 | 39 | $22,269 | $6,549 | 29.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 60 | 82 | $16,482 | $5,391 | 32.7% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2022 | 20 | 46 | $4,416 | $983.75 | 22.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 12 | 13 | $234.00 | $38.73 | 16.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 181 | 452 | $103,715 | $42,740 | 41.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 90 | $30,601 | $12,070 | 39.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 46 | 46 | $21,503 | $7,928 | 36.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 62 | 77 | $11,328 | $4,922 | 43.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $5,889 | $1,844 | 31.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 46 | 52 | $936.00 | $153.00 | 16.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 180 | 410 | $70,930 | $33,840 | 47.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 54 | 54 | $17,643 | $8,793 | 49.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 50 | 67 | $15,611 | $7,110 | 45.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 52 | 73 | $18,648 | $3,419 | 18.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 49 | 57 | $6,669 | $3,077 | 46.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 16 | 31 | $10,965 | $2,588 | 23.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 24 | 27 | $4,857 | $1,092 | 22.5% |
About Dr. Vikrant Brar, MD
Dr. Vikrant Brar, MD is a Hematology & Oncology healthcare provider based in Richmond, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1346447729.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vikrant Brar, MD has received a total of $1,311 in payments from pharmaceutical and medical device companies, with $142.82 received in 2024. These payments were reported across 53 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($972.30).
As a Medicare-enrolled provider, Brar has provided services to 1,689 Medicare beneficiaries, totaling 2,996 services with total Medicare billing of $269,711. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Richmond, VA
- Active Since 06/29/2007
- Last Updated 08/03/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1346447729
Products in Payments
- Itovebi (Biological) $120.38
- INJECTAFER (Drug) $65.07
- OPDIVO (Biological) $50.35
- DARZALEX (Biological) $47.59
- Alecensa (Biological) $42.51
- XPOVIO (Drug) $38.67
- FASLODEX (Drug) $38.63
- CALQUENCE (Drug) $38.53
- EVENITY (Biological) $32.41
- NERLYNX (Drug) $32.04
- FOUNDATIONONE (Device) $28.31
- ALIMTA (Drug) $28.05
- ZEJULA (Drug) $26.61
- Enhertu (Drug) $26.40
- PIQRAY (Drug) $24.71
- Pomalyst (Drug) $24.50
- MONOFERRIC (Drug) $20.69
- REBLOZYL (Biological) $19.86
- TASIGNA (Drug) $18.79
- OXBRYTA (Drug) $17.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Richmond
Dr. Victor Yazbeck, M.d, M.D
Hematology & Oncology — Payments: $390,374
Hematology & Oncology $390,374
Attique Samdani, M.d, M.D
Hematology & Oncology — Payments: $146,382
Hematology & Oncology $146,382
Dr. Elke Friedman, Md, MD
Hematology & Oncology — Payments: $25,274
Hematology & Oncology $25,274
Dr. Asit Paul, M.d., Ph.d.,, M.D., PH.D.,
Hematology & Oncology — Payments: $7,490
Hematology & Oncology $7,490
Dr. Ghulam Qureshi, M.d, M.D
Hematology & Oncology — Payments: $7,032
Hematology & Oncology $7,032
Gisa-Beate Schunn, M.d, M.D
Hematology & Oncology — Payments: $5,929
Hematology & Oncology $5,929